Partnership hopes to champion diversity, inclusivity, and innovation within the clinical trials sector.
Partnering with a mission to champion diversify within the clinical trials sector, The Association of Diversity in Clinical Trials (AOD) has inked an agreement to partner with BlueCloud by HealthCarePoint.com. According to a company press release, BlueCloud’s main objective is to improve clinical research efficiency while prioritizing patient well-being.
"We enthusiastically welcome BlueCloud by HealthCarePoint.com to our community," stated Diana Foster, President, AOD. "Their innovative approach seamlessly aligns with our dedication to fostering inclusivity and equality in clinical trials. Together, we're reshaping the clinical research landscape, ensuring each patient's viewpoint and experience is valued and considered."
Reference: Association of Diversity in Clinical Trials Welcomes BlueCloud by HealthCarePoint.com as a Supporting Partner. PR Newswire. September 12, 2023. Accessed September 12, 2023. https://www.prnewswire.com/news-releases/association-of-diversity-in-clinical-trials-welcomes-bluecloud-by-healthcarepointcom-as-a-supporting-partner-301922885.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.